Soluble CD137 and risk of hepatocellular carcinoma: nested case-control studies in cohorts in Shanghai and Singapore.

Autor: Thomas CE; Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA., Adibi JJ; Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA., Kuipers AL; Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA., Diergaarde B; UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.; Department of Human Genetics, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA., Luu HN; Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA., Jin A; Healthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Koh WP; Healthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Singapore Institute for Clinical Sciences, Agency for Science Technology and Research (A*STAR), Singapore, Singapore., Gao YT; Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China., Adams-Haduch J; UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA., Wang R; UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA., Lokshin A; UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.; Departments of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Behari J; UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.; Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Yuan JM; Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA. yuanj@upmc.edu.; UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. yuanj@upmc.edu.
Jazyk: angličtina
Zdroj: British journal of cancer [Br J Cancer] 2023 Jun; Vol. 128 (11), pp. 2081-2088. Date of Electronic Publication: 2023 Mar 28.
DOI: 10.1038/s41416-023-02223-z
Abstrakt: Background: The majority of hepatocellular carcinoma (HCC) cases occur in the presence of cirrhosis. Biomarkers of cirrhosis-associated immune dysfunction such as CD8+ T cell cytokines could aid HCC risk assessment.
Methods: CD8+ T cell cytokines were determined in pre-diagnostic serum in two studies including 315 HCC case-control pairs in the Shanghai Cohort Study (SCS) and 197 pairs in the Singapore Chinese Health Study (SCHS). Conditional logistic regression was used to estimate odds ratio (OR) and 95% confidence interval (CI) for HCC with levels of five cytokines-soluble CD137 (sCD137), soluble Fas (sFas), perforin, macrophage inflammatory protein 1-beta (MIP-1β), and tumour necrosis factor alpha (TNF-α).
Results: sCD137 levels were significantly higher in HCC cases than controls in both cohorts (Ps < 0.001). Compared with the lowest quartile, multivariable-adjusted ORs (95% CI) of HCC for the highest sCD137 quartile were 3.79 (1.73, 8.30) in the SCS and 3.49 (1.44, 8.48) in the SCHS. The sCD137-HCC association was independent of hepatitis B seropositivity and follow-up time. No other cytokine was consistently associated with HCC risk.
Conclusion: sCD137 was associated with higher risk of HCC in two studies nested in general population cohorts. sCD137 may be a long-term risk marker of HCC development.
(© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: